Alliance Boots explores collaboration with Nanjing Pharma to bolster Chinese presence
This article was originally published in Scrip
The European healthcare group Alliance Boots has signed a letter of intent with the Nanjing Pharmaceutical Group to co-operate for business development activities in the Chinese market.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.